Innovation Leadership
Our pharmaceutical partners are at the forefront of developing breakthrough therapies and precision medicine approaches for lung cancer treatment.
Research Excellence
Leading medical institutions and research organizations driving evidence-based advances in lung cancer detection, treatment, and care.
Global Impact
Fostering international collaboration to accelerate the translation of research discoveries into improved patient outcomes worldwide.
AstraZeneca
Leading pharmaceutical company driving innovation in oncology with breakthrough therapies and comprehensive patient care solutions for lung cancer treatment.
MSD
Committed to advancing oncology through innovative treatments and comprehensive support for lung cancer patients worldwide.
Johnson & Johnson
Committed to advancing oncology through innovative treatments and comprehensive support for lung cancer patients worldwide.
Daiichi Sankyo
Bristol Myers Squibb
National Cancer Centre Singapore
Organizing partner - National Cancer Centre Singapore
Lung Cancer Consortium Singapore
Supporting organization - Lung Cancer Consortium Singapore
Asian Thoracic Oncology Research Group
Supporting organization - Asian Thoracic Oncology Research Group
Perioperative systemic treatment for lung cancer as standard of care
[PLACEHOLDER PLACEHOLDER] - Details to be confirmed
LAURA
[PLACEHOLDER PLACEHOLDER] - Details to be confirmed
Improving outcomes in late stage EGFR mutant lung cancer
[PLACEHOLDER PLACEHOLDER] - Details to be confirmed